- Home
- EMN vs QGEN Comparison
EMN vs QGEN Comparison
Compare EMN & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EMN | QGEN |
|---|---|---|
| Founded | 1920 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 9.0B |
| IPO Year | 1996 | 1998 |
Fundamental Metrics
Financial Performance| Metric | EMN | QGEN |
|---|---|---|
| Price | $65.55 | $44.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 8 |
| Target Price | ★ $79.31 | $45.76 |
| AVG Volume (30 Days) | 896.2K | ★ 1.9M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | 4.77% | ★ 7.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.51 | N/A |
| Revenue | ★ $8,752,000,000.00 | N/A |
| Revenue This Year | $3.06 | $8.18 |
| Revenue Next Year | $3.47 | $5.71 |
| P/E Ratio | $26.12 | ★ $24.01 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $56.11 | $32.53 |
| 52 Week High | $83.47 | $57.82 |
Technical Indicators
Market Signals| Indicator | EMN | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 33.04 | 58.92 |
| Support Level | $62.26 | $41.34 |
| Resistance Level | $66.10 | $44.72 |
| Average True Range (ATR) | 1.65 | 0.95 |
| MACD | -0.57 | 0.07 |
| Stochastic Oscillator | 9.60 | 89.13 |
Price Performance
Historical ComparisonAbout EMN Eastman Chemical Company
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).